Articles on pioglitazone from NPS RADARArticles on pioglitazone from NPS RADAR

(pie-oh-GLI-tah-zone)
Title Content Type Date Description
Pioglitazone and bladder cancer: new safety advice Professional publication - NPS RADAR - Brief item 2011-08-16 00:00:09 Regulatory bodies have advised that taking pioglitazone for more than 12 months may increase the risk of bladder cancer.
Pioglitazone (Actos) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2008-04-01 00:00:00 Information on use of pioglitazone (Actos) for type 2 diabetes mellitus, including safety and dosing issues.
Pioglitazone (Actos) and rosiglitazone (Avandia) authority wording changed Professional publication - NPS RADAR - Brief item 2006-08-01 00:00:00 The wording of the PBS requirements for pioglitazone (Actos) and rosiglitazone (Avandia) changed on 1 August 2006. The changes are intended to simplify the listings, and there are no changes to the authority requirements.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-30 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.